is tirzepatide a glp 1 or glp 2 Compound Vs GLP-1 Medications: Key Differences GLP-1 meds are evolving! Retatrutide

The medication is administered once weekly via subcutaneous injection, with doses typically initiated at 2.5 mg once weekly for 4 weeks, then escalated (e.g., to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg) based on response and tolerability as per the SmPC

Certain combinations of symptoms, such as painless jaundice or persistent upper abdominal pain with weight loss, may prompt urgent referral under NICE suspected cancer guidelines (NG12)

There is no evidence to suggest Retatrutide boosts HGH, either

There is also data linking the peptide to a possible 55% rise in the average pulse area of growth hormone, indicating the amount released per pulse